

Friday 17th May, morning

Demystifying the science behind targeted treatments and immunotherapies for upper GI cancers

9.00 Registration

9.30 Biology and genetics of upper GI cancers

- An overview of the faulty genes, pathways, and processes that cause cancer
- The relationship between cancer and the immune system

Targeted therapies and immunotherapies for upper GI cancers

- Introduction to targeted therapy with antibodies and kinase inhibitors
- Introduction to immunotherapy

10.15 Questions and short break

10.25 Treating upper GI cancers with checkpoint inhibitor immunotherapy

- How checkpoint inhibitors work
- Biomarkers of response and resistance
- Combinations
- Timing – advanced vs. early; adjuvant vs. neoadjuvant

11.00 Coffee break

11.20 Treating upper GI cancers with targeted therapies

- HER2-targeted therapies for gastric/GEJ cancers
- FGFR-targeted therapies for gastric/GEJ cancers and cholangiocarcinoma
- Targeting IDH1 in cholangiocarcinoma
- Targeting CLDN18.2 with antibody-based treatments for gastric/GEJ cancers

11.50 Questions and short break

12.00 What's happening with pancreatic cancer?

- A perfect storm – the genetic, molecular and cellular makeup of pancreatic cancer
- Pancreatic cancer - targeted treatment approaches and immunotherapies that have been tried and failed
- How can we make progress against pancreatic cancer?

12.30 Close